Hurler Syndrome (Mucopolysaccharidosis Type I) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Hurler
Syndrome (Mucopolysaccharidosis Type I) Market Outlook
Thelansis’s “Hurler
Syndrome (Mucopolysaccharidosis Type I) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Hurler
Syndrome (Mucopolysaccharidosis Type I) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Hurler
Syndrome (Mucopolysaccharidosis Type I) Overview
Hurler syndrome, the most severe form
of mucopolysaccharidosis type I, is a rare autosomal recessive lysosomal
storage disorder caused by a deficiency of alpha-L-iduronidase encoded by the
IDUA gene. This results in progressive intralysosomal accumulation of dermatan
sulfate and heparan sulfate across multiple organ systems. Patients present in
infancy with coarse facial features, hepatosplenomegaly, skeletal dysostosis
multiplex, corneal clouding, and progressive neurological deterioration with
cognitive regression, causing severe disability or early mortality if
untreated. Diagnosis integrates elevated urinary glycosaminoglycans, deficient
leukocyte enzyme activity, and confirmatory IDUA sequencing. Standard
management historically relied on allogeneic hematopoietic stem cell
transplantation before two years of age to prevent progressive cognitive
decline, using intravenous laronidase as a somatic bridge. However, the
treatment paradigm has been fundamentally transformed by autologous stem cell
gene therapies like OTL-203, which provide targeted metabolic correction
without the graft-versus-host risks of allogeneic transplant. Furthermore,
historical intrathecal delivery investigations have been superseded by
blood-brain barrier-penetrating biologics. Modern neuro-enzyme replacement
therapies utilize insulin or transferrin receptor-mediated transcytosis
antibody fusions, allowing systemic weekly intravenous infusions to
successfully cross the blood-brain barrier and clear heparan sulfate from the
central nervous system. Coordinated multidisciplinary care remains mandatory to
preserve long-term survival.
Geography
coverage:
G8 (United
States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights
driven by robust research, including:
- In-depth interviews with leading KOLs
and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based
automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the most
promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment